On this page
- Understanding Brain Cancer
- Types of Brain Cancer
- Signs & Symptoms of Brain Cancer
- Risk Factors for Brain Cancer
- How Brain Cancer is Diagnosed
- Brain Cancer Staging & Prognosis (WHO 2021 CNS Classification)
- Treatment Options for Brain Cancer
- Why Adjuvant Therapy Matters in Brain Cancer
- A Day at VICI Healthcare for Brain Cancer Patients
- Brain Cancer Treatment Costs in India
- Modern vs. Traditional Brain Cancer Treatment
- Pros and Cons of Brain Cancer Treatments
- Managing Side Effects of Brain Cancer Treatment
- Frequently Asked Questions
Understanding Brain Cancer
Brain cancer comprises tumors that originate in the brain (primary tumors) or spread from other body sites (secondary tumors). Primary brain tumors account for approximately 1.5–2% of all malignancies in India, with gliomas (particularly glioblastoma) being the most common type. The WHO 2021 CNS Classification system provides the modern framework for diagnosis and prognostication, incorporating molecular markers like IDH mutation status, EGFR amplification, and TP53 alterations.
Clinical presentation varies by tumor location and size. Common symptoms include persistent headaches, seizures, vision changes, hearing problems, balance and coordination difficulties, nausea and vomiting, and cognitive or personality changes. Early detection remains challenging because symptoms often mimic other conditions. Diagnosis requires advanced imaging (MRI with contrast, sometimes PET or functional MRI) followed by tissue biopsy or stereotactic sampling for definitive pathological diagnosis and molecular profiling.
Treatment at VICI Healthcare combines multimodal approaches: maximal safe surgical resection, external-beam radiation therapy (RT), and chemotherapy (typically temozolomide). The Stupp protocol—concurrent TMZ with RT followed by adjuvant TMZ—remains the standard of care for glioblastoma. Newer strategies include tumor treating fields (TTFields), bevacizumab for recurrent disease, and precision medicine based on molecular subtyping. Prognosis depends heavily on tumor grade, histology, age, performance status, and molecular features.
Types of Brain Cancer
Glioblastoma (Grade 4 Astrocytoma)
Most aggressive and common primary brain tumor in adults. Highly infiltrative with rapid growth. WHO 2021 distinguishes IDH-wildtype (poor prognosis) from IDH-mutant (better prognosis) subtypes.
Astrocytoma (Grades 1–3)
Arise from astrocyte cells. Grade 1 (pilocytic) is slow-growing; Grade 2 (diffuse) and Grade 3 (anaplastic) show progressive aggressiveness and higher mitotic activity.
Oligodendroglioma
Typically lower-grade (WHO II–III). Often harbors 1p/19q co-deletion, which predicts chemotherapy sensitivity. Generally better prognosis than glioblastoma.
Ependymoma
Arise from ependymal cells lining ventricular system. Grade I (myxopapillary) to Grade III (anaplastic). More common in children but occur across all ages.
Medulloblastoma
Most common malignant brain tumor in children; arises in cerebellum. Highly aggressive but responsive to multimodal therapy (surgery, RT, and chemotherapy). WHO 2021 recognizes molecular subgroups affecting treatment decisions.
Atypical Teratoid/Rhabdoid Tumor (AT/RT)
Rare, aggressive tumor affecting infants and young children. INII/BAF47 loss common. Poor prognosis without intensive multimodal therapy.
Meningioma
Arises from meningeal covering. Most are benign (WHO Grade I) but can be atypical (Grade II) or malignant (Grade III). Treatment is surgery; RT reserved for high-grade or incompletely resected cases.
Brain Metastases
Secondary tumors from lung, breast, melanoma, and other cancers. Management includes surgical resection (if limited), stereotactic radiosurgery (SRS), whole-brain RT (WBRT), and systemic therapy targeting primary malignancy.
Signs & Symptoms of Brain Cancer
- Persistent headaches: Often worse in morning, may worsen with Valsalva maneuver or position change; caused by increased intracranial pressure
- Seizures: Partial focal seizures common with cortical tumors; generalized seizures occur in 20–40% of patients; may be first presenting symptom
- Vision changes: Diplopia (double vision), blurred vision, field defects, or loss of vision depending on tumor location
- Hearing loss and tinnitus: Suggest acoustic nerve or brainstem involvement; often unilateral and progressive
- Balance and coordination problems (ataxia): Indicative of cerebellar or brainstem pathology; gait disturbance and vertigo common
- Nausea and vomiting: Particularly morning vomiting; sign of increased intracranial pressure or posterior fossa involvement
- Cognitive changes: Memory loss, difficulty concentrating, slowed thinking; suggest frontal or temporal lobe involvement
- Personality or behavioral changes: Mood swings, depression, apathy, or uncharacteristic irritability; often underrecognized but distressing
- Weakness or numbness: Motor or sensory deficits in limbs on one side of body; indicates motor cortex or subcortical white matter involvement
- Speech difficulties: Slurred speech (dysarthria) or language problems (aphasia) depending on tumor location
Symptoms depend on tumor size, location, and rate of growth. Slow-growing tumors may remain asymptomatic for months. Any persistent neurological symptom warrants MRI evaluation.
Risk Factors for Brain Cancer
Most brain cancers arise sporadically without clear etiology. Known risk factors include genetic predisposition, prior radiation, and rarely occupational or viral exposures. Below are established and suspected risk factors:
| Risk Factor | How Much It Raises Risk | Notes for Indian Patients |
|---|---|---|
| Age | High | Glioblastoma and other high-grade gliomas peak in 45–65 year age group in India; medulloblastoma predominantly affects children <10 years |
| Prior cranial radiation | High | History of radiation for childhood leukemia, lymphoma, or other cancers increases risk; latency 10–30 years post-radiation |
| Hereditary syndromes (Li-Fraumeni, Neurofibromatosis Type 1 and 2, Lynch syndrome) | Moderate–High | Genetic counseling recommended for families with multiple brain tumors or early-onset cases; testing availability limited in India |
| Immunosuppression (HIV/AIDS, post-transplant) | Moderate | Primary CNS lymphoma increased in advanced HIV without adequate antiretroviral therapy; less common with modern ART |
| Occupational exposures (pesticides, petrochemicals, formaldehyde) | Low–Moderate | Epidemiological evidence mixed; agricultural workers may have increased exposure in rural India |
| Mobile phone/wireless radiation | Low | IARC classified radiofrequency radiation as possibly carcinogenic (2B category) but epidemiological studies remain inconclusive; no established causal link |
| Viral infections (EBV association with some CNS lymphomas) | Low | EBV-associated CNS lymphomas more common in immunocompromised patients; seroprevalence of EBV high across India |
Sources: ICMR (Indian Council of Medical Research) 2022 Cancer Registry; WHO GLOBOCAN 2022; NCCN Clinical Practice Guidelines
How Brain Cancer is Diagnosed
Diagnosis of brain cancer involves clinical suspicion based on symptoms, followed by imaging and tissue confirmation. The WHO 2021 CNS Classification incorporates molecular markers for accurate classification and prognostication.
-
1
Detailed neurological examination assessing mental status, cranial nerves, motor/sensory function, coordination, gait, and reflexes; detailed symptom history and timeline.
Localizes the lesion anatomically; helps prioritize imaging and differential diagnosis.
-
2
Contrast-enhanced MRI with T1, T2, FLAIR, and diffusion-weighted imaging (DWI) sequences; often supplemented by MR spectroscopy (MRS) and perfusion imaging to assess tumor grade and molecular characteristics.
Best modality for CNS pathology; enables precise localization, characterizes signal intensity and enhancement pattern, and guides surgical planning. Contrast enhancement and edema indicate blood-brain barrier disruption.
-
3
PET (fluorodeoxyglucose or amino acid tracers), resting-state fMRI, and diffusion tensor imaging (DTI) in select cases to assess metabolic activity, map eloquent cortex, and evaluate white matter tracts.
PET distinguishes recurrent tumor from radiation necrosis; functional imaging minimizes surgical morbidity by avoiding critical brain regions.
-
4
Stereotactic needle biopsy, open biopsy, or resection specimen analyzed for WHO classification (including IDH mutation, MGMT promoter methylation, TP53, EGFR amplification, 1p/19q status). Gene expression profiling (methylation array, RNA-seq) increasingly used.
Definitive diagnosis; molecular markers prognosticate and guide precision therapy. IDH-mutant gliomas have better prognosis; MGMT methylation predicts TMZ response.
-
5
Whole-spine MRI with contrast to exclude leptomeningeal spread (especially for medulloblastoma); lumbar puncture with CSF cytology if leptomeningeal involvement suspected; chest/abdomen CT or PET for high-grade tumors to exclude extracranial metastases.
Identifies stage and extent of disease; impacts treatment planning and prognosis. Leptomeningeal spread changes management significantly.
Brain Cancer Staging & Prognosis (WHO 2021 CNS Classification)
Brain tumors are staged using the WHO 2021 CNS Classification, which integrates histopathology with molecular markers. Unlike carcinomas, CNS tumors use a grading system (WHO Grades I–IV) rather than TNM staging. Grade predicts biological behavior, response to therapy, and survival.
-
Grade I (Benign)
Slow growth, low mitotic activity, minimal anaplasia. Examples: pilocytic astrocytoma, myxopapillary ependymoma, benign meningioma.
- Survival
- 10–20 year overall survival post-resection if completely resected; radiation often deferred.
- Treatment
- Surgery alone usually sufficient for completely resected tumors; radiation reserved for recurrent or unresectable disease.
-
Grade II (Low-grade)
Slow growth with some mitotic activity. Examples: diffuse astrocytoma, oligodendroglioma, atypical meningioma. May show IDH mutation.
- Survival
- 5–15 year median overall survival depending on age, resection completeness, and molecular features; IDH-mutant tumors have better prognosis than IDH-wildtype.
- Treatment
- Maximal safe resection. Observation vs. early adjuvant RT/chemotherapy debated; molecular markers guide decisions. TMZ ± RT for incompletely resected tumors.
-
Grade III (High-grade/Anaplastic)
High mitotic activity, cellular pleomorphism, possible necrosis. Examples: anaplastic astrocytoma, anaplastic oligodendroglioma. Aggressive behavior.
- Survival
- 2–5 year median overall survival depending on molecular profile and extent of resection; IDH mutations improve prognosis.
- Treatment
- Maximal resection followed by external-beam RT (54–60 Gy) with concurrent and adjuvant TMZ. Consider bevacizumab or re-irradiation at recurrence.
-
Grade IV (Glioblastoma, most aggressive)
Rapid growth, high mitotic rate, necrosis, microvascular proliferation. IDH-wildtype represents most common adult primary brain tumor; IDH-mutant form shows better prognosis.
- Survival
- Median overall survival 12–15 months with standard Stupp protocol; may reach 2 years with aggressive multimodal therapy. IDH-wildtype: ~14 months; IDH-mutant: ~24+ months.
- Treatment
- Maximal safe resection, followed by combined chemoradiation (Stupp protocol: concurrent TMZ 75 mg/m²/day during 60 Gy RT over 6 weeks, then 5 days/month TMZ for 6 months). Bevacizumab for recurrent disease. TTFields (Optune) in combination with TMZ for newly diagnosed glioblastoma shows survival benefit.
Prognosis heavily influenced by: (1) extent of resection (gross total resection [GTR] vs. subtotal [STR]); (2) molecular markers (IDH, MGMT, TP53); (3) age (<65 vs. >65 years); (4) performance status (ECOG 0–1 vs. ≥2); (5) access to multimodal therapy. Prognostic calculator tools integrating these factors available from major centers.
Treatment Options for Brain Cancer
Surgical Resection (Craniotomy)
Surgery aims for maximal safe resection while preserving neurological function. Modern neurosurgery employs intraoperative neuromonitoring, awake craniotomy with cortical mapping, endoscopy, and fluorescence-guided resection (using 5-aminolevulinic acid, 5-ALA) to identify tumor margins. The extent of resection is one of the strongest predictors of survival; gross total resection (GTR) correlates with improved outcomes across tumor grades.
For glioblastoma and high-grade gliomas, resection is followed by adjuvant radiation and chemotherapy. For lower-grade tumors and benign meningiomas, surgery may be curative if complete resection achieved. In India, advanced surgical techniques (neuronavigation, intraoperative MRI) are available at tertiary centers but may not be accessible in all regions; cost and expertise variability affect patient outcomes.
- No chemotherapy drugs administered intraoperatively
- Topical mitomycin C rarely used; not standard
External-Beam Radiation Therapy (RT)
Radiation is essential for most high-grade gliomas and medulloblastomas. Modern techniques include 3D conformal RT, intensity-modulated RT (IMRT), and proton therapy (limited availability globally and in India). Typical fractionation for glioblastoma: 60 Gy in 30 daily fractions over 6 weeks to the tumor and surrounding margin (defined by MRI). For medulloblastoma: 30–36 Gy to whole posterior fossa, 24 Gy to whole spine (for leptomeningeal seeding prevention), then boost to tumor bed.
Radiation achieves local control but crosses blood-brain barrier poorly due to tumor heterogeneity. Side effects include acute effects (fatigue, headache, nausea), early delayed effects (somnolence at 2–3 months), and late effects (cognitive decline, radiation necrosis, secondary malignancies). In India, radiation infrastructure exists at major centers; accessibility and physics support are limiting factors in smaller cities.
- Concurrent temozolomide (75 mg/m²/day throughout RT)
- 5-fluorouracil (adjuvant, less common)
- Bevacizumab (concurrent with RT in select cases)
Chemotherapy: Temozolomide (TMZ) & Alkylating Agents
Temozolomide is the backbone of chemotherapy for glioblastoma and anaplastic gliomas. The Stupp protocol (Stupp et al., 2005) established concurrent TMZ during RT (75 mg/m²/day, 7 days/week) followed by adjuvant TMZ (150–200 mg/m² on days 1–5 of a 28-day cycle for 6 months). This significantly improved median overall survival from 12.1 to 14.6 months and extended 2-year survival.
TMZ methylates DNA at the O6-guanine position. MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation predicts TMZ sensitivity; methylated tumors show longer survival. Resistance develops through acquired MGMT re-expression or other mechanisms. Dose intensity (170–200 mg/m² for 5 days/month) is tolerated in younger patients; elderly or frail patients may require dose reduction. Other alkylating agents (nitrosoureas like CCNU/lomustine, rarely used now) have lower efficacy.
In India, TMZ availability has improved but remains expensive (cost ≈ INR 50,000–80,000 per cycle); generic versions available from manufacturers. Peripheral neuropathy and myelosuppression are dose-limiting toxicities.
- Temozolomide (Temodar, Temodal) — first-line chemotherapy
- Ifosfamide — salvage therapy for recurrent disease
- Cyclophosphamide — primarily for medulloblastoma
- Lomustine (CCNU) — historical agent, less used now
- Procarbazine — component of older regimens (less common)
Targeted & Biologic Therapies
Bevacizumab, an anti-VEGF monoclonal antibody, improves progression-free survival for recurrent glioblastoma but has not improved overall survival in newly diagnosed cases. Used as monotherapy or in combination with chemotherapy/TMZ. Mechanism: reduces angiogenesis and improves blood-brain barrier function, decreasing edema.
Precision medicine approaches based on molecular profiling are emerging. Patients with specific mutations (IDH, EGFR amplification, TP53) may benefit from targeted agents in clinical trials. IDH inhibitors (e.g., ivosidenib) show promise in IDH-mutant gliomas. EGFR inhibitors (erlotinib, gefitinib) for amplified EGFR tumors remain investigational in CNS. Immune checkpoint inhibitors (pembrolizumab, nivolumab) are being studied but have not shown clear benefit in primary CNS lymphomas or glioblastomas to date.
In India, off-label use of bevacizumab is common due to cost constraints and limited access to clinical trials. Molecular testing (IDH, MGMT, EGFR) is becoming standard at large oncology centers.
- Bevacizumab (Avastin) — anti-VEGF for recurrent glioblastoma
- Ivosidenib — IDH inhibitor (in clinical trials)
- Pembrolizumab — checkpoint inhibitor (investigational)
- Nivolumab — checkpoint inhibitor (investigational)
- Erlotinib — EGFR inhibitor (off-label, investigational)
Tumor Treating Fields (TTFields)
Optune (NovoTTF-100L system) delivers low-intensity, intermediate-frequency electric fields (100–300 kHz) to disrupt microtubule dynamics during mitosis, inducing tumor cell death. FDA-approved for newly diagnosed glioblastoma in combination with TMZ based on EF-14 trial, which showed improved median overall survival (20.9 months vs. 16 months with TMZ alone).
Treatment requires wearable array patches placed directly on scalp; 18 hours daily therapy recommended. Well-tolerated with minimal systemic toxicity; localized skin irritation most common adverse effect. In India, Optune is available at select tertiary centers (major metros); cost is high (≈ INR 1.5–2.5 crores for 12 months treatment), limiting accessibility. Evidence supports combination with TMZ and potentially with bevacizumab.
- Optune (NovoTTF-100L) — tumor treating fields device, used with TMZ
Supportive & Symptomatic Therapies
Corticosteroids (dexamethasone, methylprednisolone) reduce cerebral edema and intracranial pressure; often required perioperatively and during/after RT. Anticonvulsants (levetiracetam preferred; older agents like phenytoin, valproate have drug interactions) prevent seizures. Antiemetics, proton-pump inhibitors, and DVT prophylaxis are standard supportive care. Cognitive rehabilitation, speech therapy, and physical therapy address functional deficits.
Symptom management is important for quality of life. Palliative care should be integrated early for advanced disease, addressing pain, fatigue, cognitive decline, and psychosocial needs. In India, palliative care services remain underutilized; most focus is on curative intent, often at the expense of patient comfort.
- Dexamethasone — corticosteroid for edema reduction
- Levetiracetam (Keppra) — antiepileptic drug
- Ondansetron — antiemetic
- Ranitidine or omeprazole — gastric protection during chemotherapy
Why Adjuvant Therapy Matters in Brain Cancer
Adjuvant therapy (chemotherapy and/or radiation given after surgery) is critical for glioblastoma and high-grade gliomas because surgery alone leaves microscopic disease in the infiltrative tumor margins. The Stupp protocol demonstrated that concurrent chemoradiation followed by adjuvant temozolomide extends median survival from 12 to 14.6 months, and 2-year survival from 10% to 26%—a paradigm-shifting result that remains standard care two decades later.
For lower-grade gliomas (WHO II), observation vs. early adjuvant therapy is individualized based on age, resection completeness, and molecular markers. Incompletely resected Grade II tumors and all Grade III gliomas benefit from adjuvant RT and/or chemotherapy. The goal is to delay recurrence and malignant transformation while maintaining quality of life and neurological function.
Medulloblastoma, highly aggressive in children, requires multimodal adjuvant therapy: chemotherapy (cisplatin, cyclophosphamide, etoposide—four-drug regimen) combined with craniospinal radiation and posterior fossa boost. This combination has improved 5-year survival from <10% in the 1970s to >70% today, albeit with late neurotoxicity concerns in long-term survivors.
Adjuvant therapy faces barriers in India: treatment duration stretches patient finances, travel and time constraints affect compliance, toxicity management in resource-limited settings is challenging, and some patients decline adjuvant therapy due to perceived poor prognosis or quality-of-life concerns. VICI Healthcare ensures comprehensive support—home-based chemotherapy, toxicity monitoring, cognitive rehabilitation—to maximize completion and outcomes.
A Day at VICI Healthcare for Brain Cancer Patients
-
08:00 AM
Patient arrives; important signs and laboratory work (CBC, comprehensive metabolic panel, liver/kidney function) collected if first visit or on active chemotherapy. Nurse reviews symptoms, medication adherence, and any new neurological concerns.
-
08:45 AM
Oncology consultation
physician reviews imaging, molecular reports, and treatment tolerance. For newly diagnosed patients, multidisciplinary case review (neurosurgeon, radiation oncologist, medical oncologist) recommends individualized Stupp protocol or modified regimen based on age, performance status, and molecular profile.
-
09:30 AM
Radiation planning (if on RT)
patient positioned, immobilized, and scanned for dose calculation. Advanced IMRT/conformal RT minimizes healthy brain exposure. Same-day RT if already in protocol.
-
10:30 AM
Chemotherapy administration
intravenous temozolomide or supportive care IV fluids. Nursing staff monitors infusion reactions. Duration 1–2 hours.
-
12:00 PM
Nutritionist consultation
addresses chemotherapy-related nausea, appetite loss, and dietary supportive care. Brain tumor patients often experience cognitive changes affecting self-care; nutritionist provides simplified meal plans and supplementation guidance.
-
01:00 PM
Lunch break for patient and accompanying family member. VICI Healthcare café offers nutrition-optimized meals.
-
02:00 PM
Cognitive/neuropsychological screening (if indicated)
assessment of memory, executive function, mood for early detection of chemo-fog or disease progression. Referral to cognitive rehabilitation specialist.
-
02:45 PM
Social work & care navigation
discussion of financial assistance programs (government health schemes, NGO support), logistics for follow-up, and emotional/family counseling. Coordination with home-health nursing if chemotherapy will be administered at home.
-
03:30 PM
Neurophysiotherapy session (optional)
assessment and treatment for motor deficits, balance problems, or gait disturbance. Speech therapy referral if aphasia/dysarthria present.
-
04:15 PM
Patient education
structured counseling on treatment plan, medication side effects, symptom monitoring, seizure precautions, and when to seek urgent care. Written materials in regional languages provided.
-
05:00 PM
Lab results reviewed; next appointment scheduled. Prescriptions filled (anticonvulsants, steroids, supportive medications). Patient discharged with care summary and contact information for 24/7 triage line.
Brain Cancer Treatment Costs in India
Cost varies widely based on tumor grade, treatment modality, duration, and setting (government vs. private). Below is a representative cost comparison for glioblastoma treated with Stupp protocol over 12 months in India. All figures in INR.
| Scenario | Treatment Combination | Govt Hospital | Private Hospital |
|---|---|---|---|
| Imaging & Diagnosis | MRI (3–4 scans), biopsy, molecular profiling (IDH, MGMT, sequencing) | 35,000–60,000 | 80,000–1,50,000 |
| Surgical Resection | Craniotomy + maximal resection; no intraoperative neuromonitoring | 1,50,000–2,50,000 | 4,00,000–8,00,000 |
| Surgical Resection | Craniotomy with intraoperative neuromonitoring, awake craniotomy, or intraoperative MRI | Not typically available | 8,00,000–15,00,000 |
| Radiation Therapy | 60 Gy in 30 fractions; 3D conformal or IMRT planning | 60,000–1,00,000 | 2,00,000–4,00,000 |
| Chemotherapy (Stupp Protocol) | Concurrent TMZ (6 weeks) + adjuvant TMZ (6 months); generic temozolomide | 2,50,000–4,00,000 | 5,00,000–8,00,000 |
| Chemotherapy (Stupp Protocol) | Branded temozolomide (Temodar) instead of generic | Not typically used | 7,50,000–12,00,000 |
| Tumor Treating Fields (TTFields) | 12 months of Optune therapy (18 hours daily) | Not available | 1,50,00,000–2,50,00,000 (INR 1.5–2.5 crores) |
| Supportive Care & Medications | Dexamethasone, levetiracetam, antiemetics, IV fluids, transfusions (over 6 months) | 40,000–80,000 | 1,00,000–2,00,000 |
| Total Stupp Protocol (Surgery + RT + TMZ) | Complete multimodal therapy for newly diagnosed glioblastoma | 6,50,000–10,00,000 | 18,00,000–30,00,000 |
| Recurrent Glioblastoma Treatment | Re-resection (if feasible) + bevacizumab monotherapy (8–12 months) or re-irradiation | 2,50,000–5,00,000 | 6,00,000–12,00,000 |
Costs reflect 2025–2026 estimates for major Indian cities (Delhi, Mumbai, Bangalore). Government hospital costs apply to state-run institutions; private costs vary by hospital category (tertiary superspecialty vs. mid-tier). Insurance coverage dependent on policy; many policies exclude cancer pre-diagnosis. VICI Healthcare offers payment plans, medical oncology bundling, and coordination with health schemes (Ayushman Bharat, PMJAY) to improve accessibility.
Modern vs. Traditional Brain Cancer Treatment
| Factor | Traditional Approach | VICI Healthcare Modern Approach |
|---|---|---|
| Diagnosis & Staging | Clinical exam + basic CT scan; biopsy without molecular testing; limited understanding of tumor biology | MRI with advanced sequences (DWI, MRS, perfusion), functional imaging (fMRI, DTI), PET; comprehensive molecular profiling (IDH, MGMT, TP53, EGFR, methylation array); WHO 2021 grading |
| Surgical Planning | Gross anatomical landmarks; conventional resection; intraoperative cell saver blood salvage only | 3D neuronavigation, intraoperative neuromonitoring (EMG, somatosensory/motor evoked potentials), awake craniotomy with cortical mapping, 5-ALA fluorescence, intraoperative MRI for real-time feedback |
| Extent of Resection | Subtotal resection common due to technique limitations; median survival shortened | Aggressive pursuit of gross total resection (GTR) with function preservation; GTR correlates with 30–40% longer median survival in glioblastoma |
| Radiation Therapy | 2D or basic 3D RT; larger fields; higher toxicity to surrounding brain; less individualized planning | IMRT or volumetric-modulated arc therapy (VMAT); conformal dose distribution; reduced normal tissue exposure; advanced imaging-based target delineation |
| Chemotherapy Strategy | Alkylating agents (nitrosoureas) alone, post-radiation; single-agent therapy; no concurrent approach | Stupp protocol (concurrent TMZ + RT, then adjuvant TMZ); escalated dosing in tolerant patients; combination with bevacizumab for recurrence; tailored dosing based on age/performance status |
| Treatment of Recurrence | Limited options; best supportive care; median survival from recurrence <6 months | Re-resection (if feasible), bevacizumab, re-irradiation with hypofractionated RT, clinical trial enrollment, TTFields; median progression-free survival from recurrence 4–6 months |
| Supportive Care | Steroids only; minimal symptom management; rarely multidisciplinary | Multidisciplinary team (oncology, neuro-oncology, neurosurgery, radiation, rehabilitation); cognitive rehabilitation, physiotherapy, speech therapy, nutritional support, psycho-oncology, palliative care integration |
| Personalization | One-size-fits-all protocols; age not substantially factored; no molecular guidance | Age-stratified approaches; molecular subtype-driven therapy (e.g., IDH-mutant vs. IDH-wildtype); MGMT-guided adjuvant planning; clinical trial eligibility screening; treatment de-escalation for elderly or frail patients |
| Outcomes | Median overall survival for glioblastoma ~8–10 months (pre-2005); 2-year survival <5% | Median overall survival for glioblastoma 14–16 months with Stupp; up to 20–24 months with multimodal therapy + TTFields; 2-year survival ~26–35%; better outcomes with complete… |
Pros and Cons of Brain Cancer Treatments
Surgery: Provides tissue diagnosis, cytoreduction, symptom relief, and prognostic information; however, carries risk of neurological deficits, bleeding, infection, and anesthetic complications. Eloquent cortex tumors pose functional trade-offs.
Radiation Therapy: Effective for local control and survival benefit; side effects include acute fatigue, headache, late cognitive decline (chemo-fog), radiation necrosis, and rare secondary malignancy in long-term survivors.
Temozolomide Chemotherapy: Oral bioavailability, well-tolerated in most patients, proven survival benefit (Stupp protocol); limitations include myelosuppression, nausea, hepatotoxicity, and acquired resistance over time. Cost prohibitive for some patients in India.
Bevacizumab: Improves progression-free survival and symptom control (reduces edema); does not improve overall survival in newly diagnosed glioblastoma; associated with hypertension, proteinuria, bleeding risk, and thromboembolic events.
Tumor Treating Fields (TTFields): Non-invasive, minimal systemic toxicity, device-based mechanism avoids drug resistance; requires 18 hours daily commitment, high cost (INR 1.5+ crores), requires scalp adhesion (skin irritation possible), limited evidence in other tumor types.
Combined Multimodal Therapy (Surgery + RT + Chemotherapy): Standard of care with proven long-term benefit; however, cumulative toxicity, treatment duration (months), financial burden, and psychological stress are substantial. Tolerability varies by age and comorbidities.
Medulloblastoma Protocols: Multimodal therapy achieves >70% 5-year survival in children; long-term neurotoxicity (cognitive decline, endocrine dysfunction, secondary malignancies) a concern in survivors. Requires specialized pediatric neuro-oncology centers.
Low-Grade Glioma Observation: Defers treatment toxicity and preserves quality of life initially; risk of malignant transformation, delayed diagnosis of symptomatic recurrence, patient anxiety from watchful waiting.
Precision Medicine (Molecular-Guided Therapy): Tailored treatment potential based on IDH, EGFR, TP53 status; currently experimental for most CNS tumors; limited availability, high cost of testing, and unproven benefit outside clinical trials.
Palliative Care Integration: Improves symptom control and quality of life; may be perceived as surrendering curative intent; requires early specialist referral and cultural shift in India toward earlier advance care planning.
Home-Based Supportive Care: Reduces hospital visits, improves comfort, supports family engagement; requires strong infrastructure (trained nurses, monitoring), geographic accessibility, and reliable communication systems.
Managing Side Effects of Brain Cancer Treatment
-
Surgery (Craniotomy)
- Side effects
- Neurological deficits (weakness, speech difficulty, vision loss), edema, hemorrhage, infection, seizures, CSF leak, deep vein thrombosis, anesthetic complications
- How we manage it
- Perioperative neuromonitoring, intraoperative imaging, and careful hemostasis minimize deficits. Post-op rehabilitation (physiotherapy, speech therapy) addresses functional deficits. Prophylactic levetiracetam and sequential compression devices reduce seizure…
-
Radiation Therapy (60 Gy over 6 weeks)
- Side effects
- Acute: fatigue, headache, nausea, alopecia (hair loss on scalp). Early delayed (2–3 months): somnolence, worsening cognition. Late: radiation necrosis, cognitive decline, secondary malignancy, hypopituitarism, endocrine…
- How we manage it
- IMRT/VMAT reduces normal brain dose, lowering late toxicity risk. Supportive care: antiemetics, sleep hygiene, scalp care (soft headwear). Cognitive rehabilitation addresses chemo-fog. Long-term survivors monitored…
-
Temozolomide Chemotherapy (concurrent + adjuvant)
- Side effects
- Myelosuppression (anemia, neutropenia, thrombocytopenia), nausea/vomiting, constipation, hepatotoxicity, peripheral neuropathy, secondary malignancy (rare), opportunistic infections if severe immunosuppression
- How we manage it
- CBC monitoring before each cycle; G-CSF support if neutropenia severe. Antiemetics (ondansetron, aprepitant), proton-pump inhibitors, anticonvulsant drug interactions managed. Home IV hydration if nausea limits…
-
Bevacizumab (recurrent glioblastoma)
- Side effects
- Hypertension, proteinuria/nephrotic syndrome, thromboembolic events (PE, DVT), bleeding, wound healing impairment, reversible posterior leukoencephalopathy (RPLS), congestive heart failure
- How we manage it
- Blood pressure monitoring and antihypertensive therapy (ACE inhibitor or calcium channel blocker). Urinalysis before each infusion; hold if proteinuria significant. Anticoagulation for VTE prophylaxis in…
-
Tumor Treating Fields (TTFields)
- Side effects
- Scalp irritation/dermatitis (most common), skin rash, contact dermatitis from adhesive patches, discomfort during 18-hour daily wear, device alarm fatigue, social/cosmetic concerns
- How we manage it
- Scalp hygiene protocol (gentle washing, air drying daily). Topical corticosteroid cream for irritation. Array patch rotation sites to prevent skin damage. Adjustable electrode arrays for…
-
Neurological Symptoms (from tumor or treatment)
- Side effects
- Seizures, cognitive decline (memory, executive function), mood changes (depression, anxiety), balance/gait problems, aphasia, motor weakness, personality changes
- How we manage it
- Levetiracetam prophylaxis for seizure-prone tumors; seizure action plan. Cognitive rehabilitation therapy (neuropsychologist-led), memory strategies, compensatory techniques. Antidepressants (sertraline, citalopram) for mood disturbance; psycho-oncology support. Physiotherapy…
Read the full side effects guide for Brain Cancer →
Frequently Asked Questions
What is the difference between a benign and malignant brain tumor?
Benign brain tumors (WHO Grade I, e.g., meningioma, acoustic neuroma) grow slowly and do not invade surrounding tissue or spread to distant organs. Malignant tumors (WHO Grades III–IV, e.g., glioblastoma, medulloblastoma) grow rapidly, infiltrate into normal brain tissue, and can metastasize. Prognosis and treatment intensity differ significantly; benign tumors may only require surgery, while malignant tumors require multimodal therapy. However, “benign” location in the brain can still cause significant harm if the tumor compresses critical structures.
Can brain tumors be cured?
Cure depends on tumor grade, location, molecular characteristics, and extent of resection. WHO Grade I benign tumors (especially meningiomas, acoustic neuromas) are often cured with complete surgical resection; 10–20 year recurrence-free survival is common. Lower-grade gliomas (WHO II) have better outcomes with 5–15 year survival post-resection. Glioblastoma (Grade IV) remains incurable with current standard therapy; median overall survival is 14–16 months with multimodal treatment, though individual cases vary widely. Medulloblastoma in children shows >70% 5-year survival with multimodal therapy. Advanced precision medicine (molecular-targeted therapy) and immune approaches are being studied but not yet standard.
What does “IDH mutation” mean and why does it matter?
IDH (isocitrate dehydrogenase) mutations occur in approximately 70% of lower-grade gliomas and secondary glioblastomas that arise from pre-existing lower-grade tumors. IDH-mutant tumors tend to grow more slowly, respond better to chemotherapy, have fewer additional mutations (more stable), and carry a better prognosis than IDH-wildtype tumors. IDH mutation is now part of the WHO 2021 CNS Classification and guides treatment intensity. IDH inhibitors are under investigation as targeted therapy for IDH-mutant gliomas.
What is MGMT promoter methylation and how does it affect treatment?
MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation status predicts chemotherapy sensitivity. Tumors with methylated MGMT have impaired DNA repair and respond better to alkylating agents like temozolomide; these patients show longer median overall survival (18–21 months) compared to unmethylated tumors (12–14 months) when treated with the Stupp protocol. MGMT status guides intensity of adjuvant chemotherapy; unmethylated glioblastomas may benefit from more aggressive or alternative regimens.
Why is “gross total resection” so important?
Gross total resection (GTR)—surgical removal of the entire visible tumor—is the strongest modifiable predictor of survival in glioblastoma and other high-grade gliomas. GTR is associated with 30–40% improvement in median overall survival compared to subtotal resection. Modern neurosurgical techniques (neuronavigation, intraoperative neuromonitoring, fluorescence-guided resection) allow more aggressive resection while preserving motor, sensory, and language function. Even near-total resection (95%+ volume reduction) provides benefit if GTR is not achievable.
What is the Stupp protocol and why is it standard?
The Stupp protocol, published in 2005, consists of: (1) maximal surgical resection, (2) concurrent temozolomide (75 mg/m²/day) during 6 weeks of external-beam radiation (60 Gy), followed by (3) adjuvant temozolomide (150–200 mg/m² for 5 days per 28-day cycle) for 6 months. This regimen improved median overall survival from 12.1 months (radiation alone) to 14.6 months, and 2-year survival from 10% to 26%. It became the worldwide standard of care for newly diagnosed glioblastoma and remains so after two decades because no other regimen has convincingly beaten it in phase III trials.
What are tumor treating fields (TTFields) and do they really work?
TTFields (Optune device) deliver low-intensity, intermediate-frequency (100–300 kHz) electric fields to the brain via wearable scalp electrodes. The fields disrupt cell division during mitosis, causing tumor cell death. The EF-14 trial (2015) showed that newly diagnosed glioblastoma patients treated with TMZ + TTFields had improved median overall survival (20.9 months) versus TMZ alone (16 months). Side effects are minimal (mainly scalp irritation). However, TTFields require 18 hours daily adherence, are extremely expensive (INR 1.5+ crores for 12 months), and are not universally available in India. Current evidence supports their use in combination with TMZ for newly diagnosed glioblastoma in fit patients who can afford and tolerate the commitment.
What are the risks of radiation therapy for brain tumors?
Acute side effects (during/immediately after RT) include fatigue, headache, nausea, and alopecia. Early delayed effects (2–3 months post-RT) include somnolence and temporary worsening of cognition. Late effects (>6 months, can emerge years later) include radiation necrosis (imaging mimics tumor recurrence; treated with bevacizumab or steroids), cognitive decline (“chemo-fog,” affecting memory and executive function), secondary malignancy (rare but serious), and endocrine dysfunction (hypopituitarism requiring hormone replacement). Modern IMRT/VMAT techniques minimize dose to surrounding brain, reducing toxicity risk. Careful follow-up imaging and neuropsychological testing help detect and manage late effects early.
Are there treatment options for recurrent glioblastoma?
Standard options for recurrent glioblastoma include: (1) surgical re-resection if tumor is accessible and patient is fit, (2) bevacizumab monotherapy or in combination with chemotherapy (improves median progression-free survival to 4–6 months vs. 1.5 months without), (3) hypofractionated re-irradiation (shorter course of RT, 20–30 Gy over 1–2 weeks) for selected cases, and (4) clinical trial enrollment (investigating IDH inhibitors, immunotherapy, targeted agents). Median survival from recurrence is 6–9 months with bevacizumab versus 3–4 months with best supportive care. Prognosis remains poor; early referral to specialist neuro-oncology centers is essential.
How do medulloblastoma outcomes differ from other brain tumors?
Medulloblastoma is the most common malignant pediatric brain tumor. Modern multimodal therapy (surgery, chemotherapy, craniospinal radiation, focal boost) achieves >70% 5-year survival, dramatically better than historical <10% survival. Standard chemotherapy uses cisplatin, cyclophosphamide, and etoposide given over months. WHO 2021 recognizes molecular subgroups (SHH, Group 3, Group 4, WNT) with varying prognosis; Group 4 and Group 3 are more aggressive than WNT subgroup. Long-term survivors face late effects: cognitive decline, growth hormone deficiency, infertility, and secondary malignancy. These risks necessitate lifelong follow-up and endocrine/cognitive surveillance.
Why should seizure prophylaxis be considered in brain tumor patients?
Seizures occur in 20–40% of brain tumor patients and are more common in cortical tumors (e.g., glioblastoma involving motor cortex). Levetiracetam (Keppra) is the preferred antiepileptic drug (AED) in brain tumor patients because it has minimal drug interactions with chemotherapy (unlike phenytoin or valproate) and does not induce its own metabolism. Prophylactic levetiracetam is recommended for patients with seizure risk factors (cortical tumors, grade, prior seizure). For patients without prior seizures, prophylaxis remains debated; some centers use it universally, others reserve it for high-risk tumors. Seizures significantly impact quality of life and treatment compliance, so seizure prevention is a key supportive care goal.
How does VICI Healthcare personalize brain cancer treatment for each patient?
VICI Healthcare employs a multidisciplinary approach incorporating age, performance status (ECOG score), molecular profile (IDH, MGMT, EGFR), tumor extent (imaging features, resectability), and patient preferences. For glioblastoma, fit younger patients (<70 years) are offered intensive Stupp protocol + TTFields if affordable. Elderly or frail patients (ECOG ≥2, significant comorbidities) receive hypo-intensive regimens (reduced RT dose, single-agent TMZ, or best supportive care). Lower-grade gliomas are individualized: close observation for small incompletely resected tumors vs. early adjuvant therapy for aggressive-appearing or KPS <80 cases. Home-based chemotherapy, cognitive rehabilitation, and dedicated social work ensure comprehensive support and compliance.
What role does palliative care play in brain cancer treatment?
Palliative care—focused on symptom relief and quality of life—should be integrated early alongside curative intent, not reserved for terminal stages. In brain tumors, palliative care addresses pain, nausea, seizures, cognitive decline, mood disturbance, and functional limitations. Goals include maximizing independence, supporting family coping, and ensuring comfort through disease trajectory. In India, palliative care services remain underdeveloped; VICI Healthcare bridges this gap by embedding palliative specialists from diagnosis onwards. Early discussions about advance directives, realistic prognosis, and when to transition to comfort-focused care improve patient and family satisfaction and reduce ICU-based deaths.
What support services does VICI Healthcare offer to brain cancer patients and families?
VICI Healthcare provides comprehensive support including: (1) multidisciplinary oncology consultations (medical oncology, neurosurgery, radiation oncology), (2) advanced imaging and molecular testing coordination, (3) home-based chemotherapy administration with trained nurses and 24/7 triage, (4) cognitive rehabilitation and neuropsychological monitoring, (5) nutritional support tailored to chemo-related anorexia, (6) physiotherapy and speech therapy for functional deficits, (7) psycho-oncology and social work for emotional/financial navigation, (8) financial assistance programs (government health schemes, payment plans), (9) patient education in regional languages, and (10) 24/7 medical support line for adverse events or urgent questions. These services are designed to reduce hospital visits, improve treatment tolerance, and support quality of life during and after treatment.
Medically reviewed by Oncology Team, VICI Healthcare
Last reviewed: 2026-04 | NMC Registration: [Pending]
